By Jasmin Jackson (July 15, 2022, 6:55 PM EDT) — Novo Nordisk has slapped competitor Biocon Pharma with a drug patent suit in Delaware federal court over a generic version of weight loss treatment Saxenda, contending that it’s too soon for Biocon to pursue an off-brand alternative.
Novo Nordisk Inc. says in a complaint filed Thursday that Biocon Pharma Ltd. is attempting to manufacture a Saxenda generic before the expiration of Novo’s 18 patents on the weight loss treatment that cover aspects of Saxenda’s formulation and the injection device that distributes the drug.
According to the filing, Novo Nordisk still has market exclusivity until the asserted patents expire between 2024 and…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
